19 February, 2022 - 13:34
By
Tony Quested
Apollo Therapeutics
In 2021, portfolio-based biopharma venture Apollo Therapeutics announced it was expanding its Cambridge UK and Boston US operations after raising $145 million growth capital.
The proceeds will support rapid advancement of Apollo’s pipeline with more than 15 therapeutic programs currently in development across oncology, major inflammatory disorders and rare disease.